[1]李铭一,吴静,尹元,等.华蟾素对晚期非小细胞肺癌患者证候及血清肿瘤标志物、免疫功能的影响[J].西部中医药,2024,37(05):139-142.[doi:10.12174/j.issn.2096-9600.2024.05.26]
　LI Mingyi,WU Jing,YIN Yuan,et al.The Influence of Cinobufacin on the Improvement of Syndromes, Serum Tumor Markers and Immune Function in Patients with Advanced Non-small Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(05):139-142.[doi:10.12174/j.issn.2096-9600.2024.05.26]
点击复制

华蟾素对晚期非小细胞肺癌患者证候及血清肿瘤标志物、免疫功能的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年05期
页码:
139-142
栏目:
衷中参西
出版日期:
2024-05-15

文章信息/Info

Title:
The Influence of Cinobufacin on the Improvement of Syndromes, Serum Tumor Markers and Immune Function in Patients with Advanced Non-small Cell Lung Cancer
作者:
李铭一1, 吴静1, 尹元2, 栾宝鑫3
1.上海交通大学医学院附属新华医院，上海 200092
2.上海市中西医结合医院，上海 200082
3.复旦大学附属妇产科医院，上海 200090
Author(s):
LI Mingyi1, WU Jing1, YIN Yuan2, LUAN Baoxin3
1.Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
2.Shanghai TCM-integrated Hospital, Shanghai University of TCM, Shanghai 200082, China
3.Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090， China
关键词:
非小细胞肺癌; 中医证候; 免疫功能; 华蟾素
Keywords:
non-small cell lung cancer; TCM syndromes; immune function; cinobufacin
分类号:
R734
DOI:
10.12174/j.issn.2096-9600.2024.05.26
文献标志码:
B
摘要:
目的探讨华蟾素对晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者的中医证候及血清肿瘤标志物、免疫功能的影响。 方法将120例晚期NSCLC患者采用随机数字表法分为观察组和对照组各60例。对照组患者采用化疗治疗，观察组患者采用化疗联合华蟾素片治疗。比较两组患者治疗前后各中医证候评分、肺癌生命质量量表EORTCQLQ-C30评分、中位生存时间及血清肿瘤标志物与免疫功能指标水平。 结果两组患者中医证候评分、EORTCQLQ-C30评分均较治疗前改善，且观察组改善更明显，差异均有统计学意义（P＜0.05）；观察组患者疗效指数高于对照组（P＜0.05）；观察组生存时间长于对照组（P＜0.05）；治疗后，观察组患者癌胚抗原（carcinoembryonic antigen，CEA）、细胞角蛋白19片段21-1（CYFRA21-1）、血管内皮生长因子（vascular endothelial growth factor，VEGF）等肿瘤标志物较治疗前降低，且低于对照组，差异均具有统计学意义（P＜0.05）；观察组NK、CD3+、CD4+和CD4+/CD8+较治疗前及对照组治疗后上升，差异均有统计学意义（P＜0.05）；对照组治疗后NK、CD3+，CD4+和CD4+/CD8+较治疗前下降，差异有统计学意义（P＜0.05）。 结论华蟾素可改善晚期NSCLC患者中医证候，降低血清肿瘤标志物水平及增强免疫功能，延长患者中位生存期，提高患者生存质量。
Abstract:
ObjectiveTo investigate the effects of cinobufacin on the improvement of syndromes, serum tumor markers and immune function in advanced non-small cell lung cancer (NSCLC) patients. MethodsAll 120 patients with advanced NSCLC were divided into 60 cases each in the observation group and the control group using the random number table method. The patients in the control group were treated with chemotherapy, and the patients in the observation group were treated with chemotherapy combined with cinobufacin tablet. To compare the TCM syndrome scores, EORTCQLQ-C30 scores and median survival time of the two groups before and after treatment; to compare the levels of serum tumor markers and immune function indexes of the two groups before and after treatment. ResultsThe scores of each of the TCM syndromes and EORTCQLQ-C30 scores of patients of the two groups were improved compared with those before treatment, and the patients in the observation group improved better than those in the control group, and the differences were all statistically significant (P<0.05). Therapeutic index of patients in the observation group was higher than that of the control group (P<0.05). The median survival time of the observation group was longer than that of the control group (P<0.05). After treatment, tumor markers such as (carcinoembryonic antigen, CEA), cytokeratin 19 fragment 21-1 (CYFRA21-1), and vascular endothelial growth factor (VEGF) were lower in the observation group compared with the pre-treatment period, and the observation group was lower than the control group, and the differences were all statistically significant (P<0.05). After treatment, NK, CD3+, CD4+ and CD4+/CD8+ increased in the observation group compared with the control group and before treatment, and the differences were all statistically significant (P<0.05); NK, CD3+, CD4+ and CD4+/CD8+ decreased in the control group compared with the pre-treatment period, and the differences were statistically significant (P<0.05). ConclusionTreatment of advanced NSCLC patients with cinobufacin can improve TCM syndromes, lower the levels of serum tumor markers and enhance immune function, prolong median survival and improve the patients' quality of life.

相似文献/References:

[1]宋春燕,王翠英.参芎葡萄糖联合放疗治疗局部晚期非小细胞肺癌50例临床观察[J].西部中医药,2013,26(01):89.
　SONG Chunyan,WANG Cuiying.Clinical Observation on ShenXiong Glucose Combined with Radiotherapy for 50 Cases of Local Non-small-cell Lung Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(05):89.
[2]魏海东,王晓平,万毅新,等.康艾注射液联合NP方案治疗非小细胞肺癌50例疗效观察[J].西部中医药,2012,25(09):57.
　WEI Hai-dong,WANG Xiao-ping,WAN Yi-xin,et al.Kang′ai Injection and NP Therapy in the Treatment for 50 Cases of Non-Small-Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(05):57.
[3]玛丽亚,孙学健,严兴海.新疆昌吉地区238例支气管哮喘发作期患者中医证型分布[J].西部中医药,2013,26(12):63.
　MA Liya,SUN Xuejian,YAN Xinghai.TCM Patterns Distribution of 238 Cases of Bronchial Asthma at Exacerbation Stage in Changji of XinJiang[J].Western Journal of Traditional Chinese Medicine,2013,26(05):63.
[4]席彩霞,杨国泉,苏安平,等.贞芪益气胶囊联合 GP 方案治疗晚期非小细胞肺癌的临床研究[J].西部中医药,2014,27(09):4.
[5]丁然,陆小左△.慢性乙型肝炎中医证候与舌象客观量化指标相关性的临床研究*[J].西部中医药,2015,28(01):56.
[6]周涛,何彪,霍利,等.不同证型冠心病患者螺旋CT冠状动脉CTA影像分析[J].西部中医药,2015,28(02):130.
[7]廖绛阳,张红△.血府逐瘀汤加味配合γ-刀治疗气虚血瘀证中晚期非小细胞肺癌30例[J].西部中医药,2015,28(10):98.
[8]马云飞,孙旭,杨永,等.乳腺癌的中医证型及用药规律研究[J].西部中医药,2017,30(01):46.
　MA Yunfei,SUN Xu,YANG Yong,et al.Study on TCM Syndrome and Medication Rule of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2017,30(05):46.
[9]李宁,李应福,谢兴文,等.兰州地区膝关节骨性关节炎的中医证候分布特点[J].西部中医药,2016,29(02):95.
　LI Ning,LI Yingfu,XIE Xingwen,et al.Distribution Features of TCM Syndromes of Knee Osteoarthritis in Lanzhou City[J].Western Journal of Traditional Chinese Medicine,2016,29(05):95.
[10]陈慕芝,孙红艳,照日格图△.223例类风湿关节炎患者中医证候及实验室指标分析[J].西部中医药,2016,29(05):67.
　CHEN Muzhi,SUN Hongyan,ZHAORI Getu.The Analysis of Lab Indicators and TCM Patterns of 223 Patients with Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2016,29(05):67.

备注/Memo

备注/Memo:
李铭一（1989—），男，技师。研究方向：临床生化检验项目的干扰研究。上海市卫健委青年科研项目（20174Y0016）。
更新日期/Last Update: 2024-05-15